Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DARE NASDAQ:KLTO NASDAQ:KZR NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDare Bioscience$2.11$2.29$1.83▼$9.19$28.44M1.14577,721 shs75,173 shsKLTOKlotho Neurosciences$0.59-4.6%$0.94$0.11▼$3.91$36.22M10.7416.17 million shs2.70 million shsKZRKezar Life Sciences$3.92-1.5%$4.16$3.62▼$9.18$28.69M0.6138,079 shs3,749 shsMYNZMainz Biomed$1.66-1.2%$1.72$1.30▼$16.04$7.60M0.25182,306 shs40,651 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDare Bioscience-0.94%-0.94%+3.94%-30.36%-35.28%KLTOKlotho Neurosciences+19.11%+25.03%-23.34%-61.32%+61,889,900.00%KZRKezar Life Sciences-0.50%+4.19%+2.05%-13.29%-31.14%MYNZMainz Biomed-2.33%0.00%+14.29%-8.20%-86.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDare Bioscience$2.11$2.29$1.83▼$9.19$28.44M1.14577,721 shs75,173 shsKLTOKlotho Neurosciences$0.59-4.6%$0.94$0.11▼$3.91$36.22M10.7416.17 million shs2.70 million shsKZRKezar Life Sciences$3.92-1.5%$4.16$3.62▼$9.18$28.69M0.6138,079 shs3,749 shsMYNZMainz Biomed$1.66-1.2%$1.72$1.30▼$16.04$7.60M0.25182,306 shs40,651 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDare Bioscience-0.94%-0.94%+3.94%-30.36%-35.28%KLTOKlotho Neurosciences+19.11%+25.03%-23.34%-61.32%+61,889,900.00%KZRKezar Life Sciences-0.50%+4.19%+2.05%-13.29%-31.14%MYNZMainz Biomed-2.33%0.00%+14.29%-8.20%-86.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAREDare Bioscience 3.00Buy$10.00373.93% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/AKZRKezar Life Sciences 2.33Hold$9.00129.59% UpsideMYNZMainz Biomed 2.50Moderate Buy$14.00743.37% UpsideCurrent Analyst Ratings BreakdownLatest MYNZ, KZR, KLTO, and DARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025DAREDare BioscienceMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$8.007/16/2025KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAREDare Bioscience-$17.70K-1,606.85N/AN/A($0.69) per share-3.06KLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/AKZRKezar Life Sciences$7M4.10N/AN/A$16.02 per share0.24MYNZMainz Biomed$890K8.54N/AN/A$2.61 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAREDare Bioscience-$4.05M-$2.14N/AN/AN/AN/AN/A-103.70%11/13/2025 (Estimated)KLTOKlotho Neurosciences-$6.15M-$0.45N/A∞N/AN/A-325.88%-242.15%N/AKZRKezar Life Sciences-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%11/11/2025 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest MYNZ, KZR, KLTO, and DARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025KLTOKlotho NeurosciencesN/A-$0.12N/A-$0.12N/AN/A8/14/2025Q2 2025DAREDare Bioscience-$0.55-$0.45+$0.10-$0.45$0.14 million($0.02) million8/13/2025Q2 2025KZRKezar Life Sciences-$2.15-$1.87+$0.28-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAREDare BioscienceN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAREDare BioscienceN/A0.340.34KLTOKlotho NeurosciencesN/A135.73135.73KZRKezar Life Sciences0.037.297.29MYNZMainz Biomed0.141.321.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAREDare Bioscience6.70%KLTOKlotho Neurosciences20.07%KZRKezar Life Sciences67.90%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipDAREDare Bioscience4.80%KLTOKlotho Neurosciences26.70%KZRKezar Life Sciences10.40%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAREDare Bioscience3013.48 million12.83 millionNot OptionableKLTOKlotho NeurosciencesN/A61.37 million44.99 millionN/AKZRKezar Life Sciences607.32 million6.56 millionNot OptionableMYNZMainz Biomed304.58 million3.75 millionNot OptionableMYNZ, KZR, KLTO, and DARE HeadlinesRecent News About These CompaniesMainz Biomed Announces Registration of ColoAlert in the United KingdomSeptember 2, 2025 | globenewswire.comMainz Biomed receives Swiss regulatory approval to market ColoAlertAugust 14, 2025 | msn.comMainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®August 13, 2025 | globenewswire.comMainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and WarrantsAugust 4, 2025 | globenewswire.comMainz Biomed files to sell 1.47M ordinary unitsJuly 31, 2025 | msn.comEQS-News: Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance CompaniesJuly 24, 2025 | finanzen.atFMainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance CompaniesJuly 23, 2025 | globenewswire.comMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15, 2025 | globenewswire.comMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15, 2025 | globenewswire.comMainz Biomed BV News (MYNZ) - Investing.comJuly 4, 2025 | investing.comMainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von BauchspeicheldrüsenkrebsJune 25, 2025 | anlegerplus.deAMainz BioMed NV: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | finanznachrichten.deMainz Biomed BV Aktie | MYNZ Kurs | Realtime - Investing.comJune 25, 2025 | de.investing.comEQS-News: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von BauchspeicheldrüsenkrebsJune 25, 2025 | boerse.deBMainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | globenewswire.comPromising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy RatingJune 11, 2025 | tipranks.comMainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finanznachrichten.deMainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von BauchspeicheldrüsenkrebsJune 10, 2025 | anlegerplus.deAMainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finance.yahoo.comMainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert ProjectJune 10, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYNZ, KZR, KLTO, and DARE Company DescriptionsDare Bioscience NASDAQ:DARE$2.11 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.12 +0.01 (+0.24%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Klotho Neurosciences NASDAQ:KLTO$0.59 -0.03 (-4.64%) As of 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Kezar Life Sciences NASDAQ:KZR$3.94 -0.05 (-1.13%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Mainz Biomed NASDAQ:MYNZ$1.66 -0.02 (-1.19%) Closing price 04:00 PM EasternExtended Trading$1.66 +0.01 (+0.30%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
